Medical Isotope Production Companies
.png)
Published: September 2025
Isotopes are distinct nuclear forms of a chemical element that share the same number of protons and electrons, however, differ in neutron count, resulting in different atomic masses. In recent years, isotopes have become integral to modern medicine, particularly in diagnostics and therapeutic applications for various diseases, including cancer. Notably, more than 40 million medical procedures utilizing isotopes are performed globally each year, offering critical insights into organ function and the progression of diseases. For instance, Cobalt-60 is widely recognized as the most common isotope used in radiation therapy and for sterilization purposes in healthcare settings.
We analyzed leading companies engaged in the domain of medical isotopes. In this article, discover top 11 medical isotope production companies and their strength in the diagnostic industry.
In recent years, there has been a surge in prevalence of chronic conditions like cancer and cardiovascular disorders; these conditions significantly impact the patients’ overall well-being (due to reduced mobility and a lower quality of life) and therefore, medical isotopes have emerged as the most prominent causes of death and disability, globally. In fact, as per a recent report published by the World Health Organization, it is anticipated that by 2050, there will be more than 35 million new cancer cases, indicating approximately 80% rise from the cases reported in 2022. Diagnostic isotopes, such as Technetium-99m (used in ~80% of nuclear medicine scans) and Fluorine-18 (critical for PET imaging), provide detailed insights into organ function and tissue abnormalities, enabling early and accurate detection of conditions.
Roots Analysis has conducted an exhaustive study on Medical Isotope Production Market featuring the current market landscape and future opportunity for the companies engaged in the domain of diagnostics, over a span of 10 years.
Table of Contents
Below, we have listed (in alphabetical order), the top 11 medical isotope production companies.
- Actinium Pharmaceuticals
- Fussion Pharmaceuticals
- IRE
- Jubilant Radiopharma
- Kinectrics
- Lantheus
- Novartis
- NTP Radioisotopes
- Siemens Healthineers
- Taiyo Nippon Sanso
- Telix Pharmaceuticals
Discover Below the Details on Top 11 Medical Isotope Production Companies
Let us deep dive to understand the activity of the 11 top medical isotope production companies. It is essential to note that the selection of top players can differ substantially according to the defined criteria.
Actinium Pharmaceuticals Announced Advance Build-Out of its In-house Manufacturing Facility by 2Q 2025
1. Actinium Pharmaceuticals
Actinium Pharmaceuticals is a global leader in the manufacturing of novel drug targeted radiotherapies that enable effective treatment of blood cancer. It is worth highlighting that through its proprietary cyclotron-based technology the company produces high grade Actinium-225 isotope which is used in radiotherapy. Moreover, the company emphasizes creating a positive therapeutic impact by creating novel antibody radiation conjugates and ensuring targeted combination therapies.
Actinium Pharmaceuticals: Company Overview
| Key Parameters | Description |
| Company Logo |  |
| Year of Establishment | 2000 |
| Number of Employees | 11-50 |
| Headquarters |  |
| Isotope Offered |
|
In March 2025, Actinium Pharmaceuticals announced plans for an in-house manufacturing facility to produce high-purity Actinium-225, aiming to secure a reliable domestic supply of this critical radioisotope to support the development of Actimab-A and other pipeline candidates for US and international clinical trials. This initiative is expected to reduce dependence on external suppliers, enhance supply chain control, and accelerate Actinium's radiotherapeutic development programs.
Further details on recent initiatives taken by Actinium Pharmaceuticals and other medical isotope production companies have been provided in detail in the report.
In June 2024, Fusion Pharmaceuticals Has Been Acquired by AstraZeneca to Gain Access to R&D and Manufacturing of Actinium Based Radiopharmaceuticals
2. Fusion Pharmaceuticals
Fusion Pharmaceuticals is a clinical stage radiopharmaceutical firm specializing in developing next generation radiopharmaceuticals for precision oncology. Further, the company utilizes isotopes (that emit short range alpha particles) in combination with targeted antibodies to induce precise cancer cell death. In addition to this, the company’s pipeline includes various programs including FPI-2265, FPI-1434 and FPI-2059, to effectively evaluate the potential of isotopes such as Actinium-225 for cancer therapy.
Fusion Pharmaceuticals: Company Overview
| Particulars | Specifications |
| Company Logo |  |
| Year of Establishment | 2014 |
| Number of Employees | 11-50 |
| Headquarters |  |
| Isotope Offered | Actinium-225 |
In May 2023, Fusion Pharmaceuticals opened a new 27,000-square-foot, Good Manufacturing Practice (GMP)-compliant radiopharmaceutical manufacturing facility in Hamilton, Ontario, to produce targeted alpha therapies for cancer.
Further details on recent initiatives taken by Fusion Pharmaceuticals and other medical isotope production companies have been provided in detail in the report.
ITM Isotope Technologies Munich Has Large-Scale Lutetium-177 Manufacturing Capability
3. ITM Isotope Technologies Munich
ITM Isotope Technologies Munich claims to be a pioneer in the field of radiopharmaceuticals. The company specializes in providing an array of radioisotopes for both clinical applications and research purposes. In fact, the company is looking forward to novel targeting approaches wherein it combines radioisotopes with different targets such as antibodies, peptide therapeutics and small molecules facilitating their use in multiple cancer indications.
ITM Isotope Technologies Munich: Company Overview
| Particulars | Specifications |
| Company Logo |  |
| Year of Establishment | 2004 |
| Number of Employees | 500-1,000 |
| Headquarters |  |
| Isotope Offered |
|
ITM operates world-leading manufacturing facilities for medical isotopes, including the world’s largest production site for lutetium-177 at Neufahrn near Munich, Germany, supporting global demand for targeted cancer therapies. Further, In June 2025, ITM Isotope Technologies Munich (ITM) and the Institut Laue-Langevin (ILL) extended their partnership, first established in 2009. The agreement provides ITM with priority access to 50% of the neutron irradiation capacity at ILL’s High-Flux Reactor, enabling expanded production of non-carrier-added Lutetium-177 (n.c.a. Lu-177) - a key radioisotope for cancer radiopharmaceutical therapies.
Further details on recent initiatives taken by ITM Isotope Technologies Munich and other medical isotope production companies have been provided in detail in the report.
Jubilant Radiopharma is a Subsidiary of Jubilant Pharma Limited
4. Jubilant Radiopharma
Jubilant Radiopharma is a global leader in the development, manufacturing, and distribution of radiopharmaceuticals. The company specializes in providing high-quality nuclear medicine products used for diagnostic imaging and nuclear therapy applications. These include solutions for lung, thyroid, bone, cardiac imaging, and thyroid disease therapy.
Jubilant Radiopharma: Company Overview
| Particulars | Specifications |
| Company Logo |  |
| Year of Establishment | 2019 |
| Number of Employees | 1,00-5,000 |
| Headquarters |  |
| Isotope Offered |
|
In October 2024, the company partnered with Ion Beam Applications (IBA) to install IBA’s Cyclone® KIUBE 180 cyclotrons and associated instruments, thereby expanding its PET radioisotope production capacity across the US.
Further details on recent initiatives taken by Jubilant Radiopharma and other medical isotope production companies have been provided in detail in the report.
Kinectrics Has a Notable Presence in Seven Countries, Operating 19 Locations Worldwide, and is a Trusted Partner Across the Healthcare Sector, Empowering Clients to Advance Their Research Capabilities
5. Kinectrics
Kinectrics is a prominent medical isotope manufacturing firm, involved in the development of both, diagnostic and therapeutic medical isotopes, that can be used for the treatment of different chronic diseases. Further, the company provides radioactive waste management processes such as selective carbon extraction process to enhance the safety and efficiency of nuclear facilities.
Kinectrics: Company Overview
| Particulars | Specifications |
| Company Logo |  |
| Year of Establishment | 1912 |
| Number of Employees | 1,00-5,000 |
| Headquarters |  |
| Isotope Offered |
|
Kinectrics has been a part of the Isotope Production System (IPS) project, along with Bruce Power and Isogen, to enhance the production of medical isotopes. Through this project, Kinectrics utilizes CANDU reactors to produce both imaging and therapeutic medical isotopes, such as Lutetium-177. This system significantly enhances the supply of Lutetium-177 while adhering to the stringent regulatory guidelines. Further, by guaranteeing high quality, safety and minimum carbon emissions, the isotopes produced via CANDU reactors are optimized for use in clinical settings.
Further details on recent initiatives taken by Kinectrics and other medical isotope production companies have been provided in detail in the report.
Lantheus Integrates its AI Software Platforms With Its Medical Isotopes to Optimize Isotope-based Imaging Techniques, Resulting in Enhanced Image Quality, Faster Processing Times, and Improved Diagnostic Accuracy
6. Lantheus
With a strong history of more than 65 years, Lantheus has established itself as one of the active firms in the radiopharmaceutical market. Notably, through its crucial partnerships and groundbreaking innovations the company has grown significantly over time. Further, the company focuses on producing isotopes, such as, Technetium-99m utilized for effective medical imaging.
Lantheus: Company Overview
| Particulars | Specifications |
| Company Logo |  |
| Year of Establishment | 1956 |
| Number of Employees | 500-1,000 |
| Headquarters |  |
| Isotope Offered |
|
In May 2025, SHINE Technologies announced to acquire the SPECT business from Lantheus. Further, SHINE Technologies also plans to acquire Lantheus’ SPECT Division with an intend to expand its market reach and leadership in nuclear medicine.
Further details on recent initiatives taken by Lantheus and other medical isotope production companies have been provided in detail in the report.
Novartis is Actively Investing in In-House Isotope Production to Address A Global Shortage and Support Its Radioligand Therapy (RLT) Pipeline
7. Novartis
Novartis is a healthcare company focused on the discovery and manufacturing of generic pharmaceutical and eye care products. Further, it is worth noting that RLTs consist of a targeting compound, known as the ligand, which attaches to a specific marker, along with a radioisotope thereby directing the radioisotopes to the specific target cancer cells. This renders minimal side effects to healthy cells. The company’s product portfolio includes radioisotopes such as Lutetium-177 for developing RLTs for various cancer types.
Novartis: Company Overview
| Particulars | Specifications |
| Company Logo |  |
| Year of Establishment | 1996 |
| Number of Employees | 10,001+ |
| Headquarters |  |
In September 2024, the company expanded its radioligand therapy manufacturing and supplying capabilities through the opening of two new manufacturing facilities in the US; the new facility is likely to increase the capacity for the production of isotopes which are crucial for the development of radioligand therapies facilitating cancer treatment.
Further details on recent initiatives taken by Novartis and other medical isotope production companies have been provided in detail in the report.
NTP Radioisotopes is a Subsidiary of South African Nuclear Energy Corporation (NECSA)
8. NTP Radioisotopes
NTP Radioisotopes is renowned for its capabilities to produce and supply some of the important medical radioisotopes such as molybdenum-99, iodine-131 and lutetium-177. It is worth mentioning that the company’s drug development pipeline features several promising candidates against different oncological indications.
Apart from this, the company also offers products, such as radionuclide production generators, radiolabeling kits and radiopharmaceutical capsules to support the manufacturing of radiopharmaceuticals focused on facilitating effective diagnosis and treatment.
NTP Radioisotopes: Company Overview
| Particulars | Specifications |
| Company Logo |  |
| Year of Establishment | 1992 |
| Number of Employees | 201-500 |
| Headquarters |  |
| Isotope Offered |
|
In October 2024, the company extended its technology transfer and license agreement with ITM Isotope Technologies Munich in order to continue producing Leutetium-177 radioisotope.
Further details on recent initiatives taken by NTP Radioisotopes and other medical isotope production companies have been provided in detail in the report.
Siemens Healthineers Emphasizes Personalized Care, Precision Therapy and Technology Enabled Workflow Operations to Assist Physicians in Making Technology Validated Decisions
9. Siemens Healthineers
Siemens Healthineers is a medtech company that offers a comprehensive array of products, services and solutions designed to facilitate medical assistance to both medical professionals and patients. With its presence in over 70 countries the company claims to offer high-quality and cost-effective medical products to support healthcare systems worldwide.
Further, through its subsidiary, PETNET solutions, the company provides positron emission tomography radiopharmaceuticals that aid in early diagnosis of chronic diseases.
Siemens Healthineers: Company Overview
| Particulars | Specifications |
| Company Logo |  |
| Year of Establishment | 1847 |
| Number of Employees | 10,001+ |
| Headquarters |  |
| Isotope Offered |
|
In January 2025, the company entered into a collaboration with Canadian Nuclear Isotope Council to provide its advanced isotope based medical imaging and diagnostic technology across Canada.
Further details on recent initiatives taken by Siemens Healthineers and other medical isotope production companies have been provided in detail in the report.
Taiyo Nippon Sanso Claims to Produce High Quality Stable Isotopes Such as Oxygen-18 Which Are Used in Positron Emission Tomography (PET) for Effective and Early Detection of Diseases
10. Taiyo Nippon Sanso
Taiyo Nippon Sanso is a multinational company renowned for its healthcare technology. The company has effectively used its unique skills in high purity gas production to produce and deliver essential medical isotopes specifically stable isotopes. It is worth highlighting that by leveraging its cryogenic air separation technology, the company has developed a remarkable process for the efficient separation of oxygen isotopes.
Taiyo Nippon Sanso: Company Overview
| Particulars | Specifications |
| Company Logo |  |
| Year of Establishment | 1910 |
| Number of Employees | 10,001+ |
| Headquarters |  |
| Isotope Offered | Oxygen-18 |
Further details on recent initiatives taken by Taiyo Nippon Sanso and other medical isotope production companies have been provided in detail in the report.
Telix Pharmaceuticals is Actively Involved in Both Developing and Acquiring Technologies for Radioisotope Production, Particularly for Medical Applications
11. Telix Pharmaceuticals
Telix Pharmaceuticals is an early-stage biopharmaceutical company focused on delivering precision medicine through targeted radiation. The company claims to offer products for treatment of various types of cancers, such as brain cancer, prostate cancer, renal cancer as well as a range of immunologic and rare diseases. For this, the company utilizes radioisotopes combined with a targeting agent such as antibody to design radiopharmaceutical drugs that can be used either for imaging or delivering of a therapy. Notably, the company offers a broad portfolio of innovative products that support clinicians to offer better outcomes for patients.
Telix Pharmaceuticals: Company Overview
| Particulars | Specifications |
| Company Logo |  |
| Year of Establishment | 2015 |
| Number of Employees | 500-1,000 |
| Headquarters |  |
| Isotope Offered |
|
In September 2024, the company acquired RLS. This acquisition allows Telix to expand its North American manufacturing and distribution platform.
Further details on recent initiatives taken by Telix Pharmaceuticals and other medical isotope production companies have been provided in detail in the report.
What About the Other Medical Isotope Production Companies Around the World?
The above presentation features 11 top medical isotope production companies selected from a pool of ~110 players that we have compiled. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.
Sources
- https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-announces-supply-agreement-with-eckert--ziegler-for-ac-225-radioisotope-to-support-comprehensive-development-activities-302409600.html
- https://www.itm-radiopharma.com/news/press-releases/press-releases-detail/ITM,_TUM,_and_TUM_University_Hospital_Sign_New_Framework_Agreement_to_Advance_Innovative_Radiopharmaceutical_Cancer_Treatments-678/
- https://www.indianpharmapost.com/news/jubilant-draximage-o-invest-us-50-million-to-expand-its-pet-radiopharmacy-network-15770
- https://fox59.com/business/press-releases/cision/20250506CG79189/shine-technologies-announces-plan-to-acquire-lantheus-spect-division-expanding-market-reach-and-leadership-in-nuclear-medicine/
- https://www.novartis.com/us-en/news/media-releases/novartis-begins-construction-two-new-radioligand-therapy-facilities-us-expanding-its-world-class-rlt-manufacturing-and-supply-network
- https://www.itm-radiopharma.com/news/press-releases/press-releases-detail/ITM_and_NTP_Strengthen_Global_Radioisotope_Production_Capacities_by_Renewing_their_Technology_License_Agreement_and_Signing_a_Manufacturing_and_Supply_Agreement_for_n.c.a._Lutetium-177-676/
- https://www.canadianisotopes.ca/the-cnic-announces-partnership-with-siemens-healthineers-to-increase-access-to-life-changing-medical-imaging-and-diagnostic-technology-across-canada/
- https://telixpharma.com/news-views/telix-to-acquire-rls-to-expand-north-american-manufacturing-and-distribution-platform/
- https://www.shinefusion.com/blog/shine-to-acquire-lantheus-spect
- https://www.kinectrics.com/projects/medical-isotope-production-system-design-fabrication-installation
- https://www.iba-worldwide.com/iba-partners-jubilant-radiopharma-selling-five-cycloner-kiube-support-their-pet-radioisotope
- https://www.globenewswire.com/news-release/2023/06/13/2686811/0/en/ITM-Opens-World-s-Largest-Lutetium-177-Production-Facility-for-Targeted-Radionuclide-Therapies-Against-Cancer.html
- https://www.globenewswire.com/news-release/2025/06/16/3099616/0/en/ITM-and-ILL-Extend-Collaboration-on-the-Manufacturing-and-Supply-of-Medical-Lutetium-177-Radioisotope.html
- https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-announces-opening-of-radiopharmaceutical-manufacturing-facility-to-produce-targeted-alpha-therapies-for-cancer-301813745.html